Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 9/20 | 0.69 |
| ▸ | TACR1 | P25103 | 4/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | CCR5 | P51681 | 3/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3689703 | 0.93 | TACR1 (0.67) | OPRM1TACR1LMNAGAAMAPT | |
| SCHEMBL3650479 | 0.91 | TACR1 (0.66) | OPRM1TACR1LMNAGAAMAPT | |
| SCHEMBL3757984 | 0.91 | OPRM1 (0.76) | OPRM1TACR1ACHECNR2CCR5 | |
| SCHEMBL3764460 | 0.89 | OPRM1 (0.65) | OPRM1TACR1ACHEOPRD1 | |
| SCHEMBL3647412 | 0.87 | OPRM1 (0.57) | OPRM1TACR1OPRD1 | |
| SCHEMBL8564833 | 0.87 | OPRM1 (0.83) | OPRM1TACR1OPRD1 | |
| SCHEMBL3686831 | 0.86 | OPRM1 (0.56) | OPRM1TACR1ACHE | |
| SCHEMBL3694300 | 0.83 | OPRM1 (0.52) | OPRM1TACR1ACHEOPRD1 | |
| SCHEMBL8568874 | 0.82 | OPRM1 (0.81) | OPRM1TACR1LMNAGAAMAPT | |
| SCHEMBL3647404 | 0.82 | OPRM1 (0.47) | OPRM1TACR1GAAMAPTACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298380-A1 | N-ARYL-N-PIPERIDIN-4-YLMETHYL-AMIDE DERIVATIVES AND THIER USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2010-11-25 | — | — | US | claimed |
| US-20100298380-A1 | N-ARYL-N-PIPERIDIN-4-YLMETHYL-AMIDE DERIVATIVES AND THIER USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298380-A1 | N-ARYL-N-PIPERIDIN-4-YLMETHYL-AMIDE DERIVATIVES AND THIER USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC6A4 | OPRM1 124/4885TACR1 83/4885LMNA 4411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.